Literature DB >> 18830681

Assessing the role of stress signalling via p38 MAP kinase in the premature senescence of ataxia telangiectasia and Werner syndrome fibroblasts.

Terence Davis1, David Kipling.   

Abstract

The premature ageing ataxia telangiectasia (AT) and Werner syndromes (WS) are associated with accelerated cellular ageing. Young WS fibroblasts have an aged appearance and activated p38 MAP kinase, and treatment with the p38 inhibitor SB230580 extends their lifespan to within the normal range. SB203580 also extends the replicative lifespan of normal adult dermal fibroblasts, however, the effect is much reduced when compared to WS cells, suggesting that WS fibroblasts undergo a form of stress-induced premature senescence (SIPS). A small lifespan extension is seen in AT cells, which is not significant compared to normal fibroblasts, and the majority of young AT cells do not have an aged appearance and lack p38 activation, suggesting that the premature ageing does not result from SIPS. The lack of p38 activation is supported by the clinical manifestation, since AT is not associated with inflammatory disease, whereas WS individuals are predisposed to atherosclerosis, type II diabetes and osteoporosis, conditions known to be associated with p38 activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830681     DOI: 10.1007/s10522-008-9179-x

Source DB:  PubMed          Journal:  Biogerontology        ISSN: 1389-5729            Impact factor:   4.277


  13 in total

1.  p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype.

Authors:  Adam Freund; Christopher K Patil; Judith Campisi
Journal:  EMBO J       Date:  2011-03-11       Impact factor: 11.598

2.  Depletion of WRN protein causes RACK1 to activate several protein kinase C isoforms.

Authors:  L Massip; C Garand; A Labbé; E Perreault; R V N Turaga; V A Bohr; M Lebel
Journal:  Oncogene       Date:  2009-12-07       Impact factor: 9.867

3.  Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome.

Authors:  Terence Davis; Hannah S E Tivey; Amy J C Brook; Julia W Grimstead; Michal J Rokicki; David Kipling
Journal:  Age (Dordr)       Date:  2012-09-22

4.  Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors.

Authors:  Terence Davis; Matthew C Dix; Michal J Rokicki; Amy Jc Brook; Caroline S Widdowson; David Kipling; Mark C Bagley
Journal:  Chem Cent J       Date:  2011-12-08       Impact factor: 4.215

Review 5.  Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.

Authors:  Mark C Bagley; Terence Davis; Paola G S Murziani; Caroline S Widdowson; David Kipling
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-04

6.  p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes.

Authors:  Hannah S E Tivey; Amy J C Brook; Michal J Rokicki; David Kipling; Terence Davis
Journal:  Biogerontology       Date:  2012-10-31       Impact factor: 4.277

7.  The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome.

Authors:  Terence Davis; Michal J Rokicki; Mark C Bagley; David Kipling
Journal:  Chem Cent J       Date:  2013-01-29       Impact factor: 4.215

8.  Small molecule inhibition of p38 MAP kinase extends the replicative life span of human ATR-Seckel syndrome fibroblasts.

Authors:  Hannah S E Tivey; Michal J Rokicki; James R Barnacle; Matthew J Rogers; Mark C Bagley; David Kipling; Terence Davis
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-02-11       Impact factor: 6.053

9.  Nijmegen breakage syndrome fibroblasts expressing the C-terminal truncated NBN(p70) protein undergo p38/MK2-dependent premature senescence.

Authors:  Terence Davis; Hannah S E Tivey; Amy J C Brook; David Kipling
Journal:  Biogerontology       Date:  2014-09-12       Impact factor: 4.277

10.  Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.

Authors:  Dauren Alimbetov; Terence Davis; Amy J C Brook; Lynne S Cox; Richard G A Faragher; Talgat Nurgozhin; Zhaxybay Zhumadilov; David Kipling
Journal:  Biogerontology       Date:  2015-09-23       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.